Delivery Order SPE2DB25D2207-SPE2DB25FQRRB
- Not listed
- The Defense Logistics Agency awarded a $10,016.78 delivery order to AmerisourceBergen Drug Corp on September 5, 2025, for the supply of Zepbound 2.5 mg/0.5 mL pen injections. This firm fixed price contract, with an ultimate completion date of September 8, 2025, represents a non-competitive delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract vehicle with DLA Troop Support Medical. The pharmaceutical product will be delivered to AmerisourceBergen's corporate...
- The Defense Logistics Agency (DLA) awarded a $12,636.36 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound 10 mg/0.5 ml pen injections on August 29, 2025, with a completion date of September 2, 2025. This delivery order represents a child contract under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The award was competitively awarded with no set-aside designation and...
- The Defense Logistics Agency awarded a delivery order valued at $12,539.80 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 ml pen injectors on July 31, 2025. This firm fixed-price, competitively awarded delivery order will be fulfilled from the vendor's Conshohocken, Pennsylvania facility, with an ultimate completion date of August 1, 2025. The contract carries no set-aside designation and represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on May 2, 2025, for the supply of Zepbound 2.5 mg/0.5 ml pen injections. This competitively awarded, non-set-aside contract has a ceiling value of $10,683.61 with a firm fixed price structure and is scheduled for completion by May 5, 2025. The award will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $10,856.00 to AmerisourceBergen Drug Corp for the supply of Zepbound 2.5 mg/0.5 ml pen injections on August 26, 2025, with an ultimate completion date of August 27, 2025. This firm fixed-price delivery order represents a non-competitive, non-set-aside award executed under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December...
- The Defense Logistics Agency awarded a delivery order valued at $6,921.52 to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Zepbound 5 mg/0.5 mL pen injectors. The contract, designated as a firm fixed price delivery order with an ultimate completion date of July 30, 2025, will be fulfilled at the contractor's facility in Conshohocken, Pennsylvania. This award was competitively awarded with no set-aside designation and represents a child contract under AmerisourceBergen's...
- The Defense Logistics Agency awarded a $3,292.56 delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Zepbound 5 mg/0.5 mL pen injectors with an ultimate completion date of August 19, 2025. This is a firm fixed-price contract with no set-aside designation, competitively awarded under an open procurement process. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. As a child contract, this delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $13,146.50 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 ml pen injections on August 27, 2025, with an ultimate completion date of August 28, 2025. This firm fixed-price delivery order was awarded without set-aside designation through open competition, reflecting the vendor's demonstrated capability to meet federal pharmaceutical procurement requirements. The contract is performed at AmerisourceBergen's...
- The Defense Logistics Agency awarded a $4,575.54 firm fixed price delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injections. The order, which represents a child contract under AmerisourceBergen's larger indefinite delivery vehicle with DLA Troop Support Medical, is scheduled for completion by September 16, 2025, and will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. This delivery order was...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $3,054.70 by the Defense Logistics Agency (DLA) on August 25, 2025, for the supply of Zepbound 10 mg/0.5 mL pen injections. The contract utilizes firm fixed pricing with no set-aside designation, indicating competitive award, and requires completion by August 26, 2025. The pharmaceutical distributor will fulfill this order from its corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- SPE2DB25D2207Indefinite Delivery Contract
- SPE2DB25D2207-SPE2DB25FQRRBDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $9,119.37 to AmerisourceBergen Drug Corp for the supply of Zepbound 2.5 mg/0.5 ml pen injections on September 3, 2025, with an ultimate completion date of September 4, 2025. This firm fixed price delivery order was competitively awarded without set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026, which serves as a comprehensive global pharmaceutical support vehicle. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, supplies a broad range of medications and medical commodities to support military and veteran healthcare systems. The Zepbound delivery under this order contributes to the broader pharmaceutical supply chain supporting Defense Health Agency and other federal healthcare customers. The company's substantial IDC with DLA reflects its established capability to meet federal procurement requirements across multiple therapeutic domains, positioning it as a critical vendor for military medical supply needs globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $9.1k | 9/3/25 |